1-4 of 4
Charles Jonassaint
Close
Sort by
Journal Articles

Trends of Disease Modifying Treatment Use in Sickle Cell Disease: Retrospective Analysis of Claims Data, 2014-2020

Terri Newman, Jingye Yang, Kangho Suh, Charles Jonassaint, Sandra Kane-Gill, Enrico M Novelli
Journal: Blood
Blood (2022) 140 (Supplement 1): 1389–1390.
https://doi.org/10.1182/blood-2022-159197
Published: 2022
Journal Articles

Assessing the Validity of the Brief Pain Inventory for Use Among Adults with Sickle Cell Disease

Jordan Driscoll, BA, Mikhil Bamne, PhD, Charles Jonassaint, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5579.
https://doi.org/10.1182/blood.V130.Suppl_1.5579.5579
Published: 2017
Journal Articles

Using Social Media to Assess Patient and Family Perceptions of Bone Marrow Transplant, Gene Therapy and Other Potentially Curative Treatments for Sickle Cell Disease (SCD)

Charles Jonassaint, PhD, Aisha L Walker, PhD MPH, Rosta Farzan, PhD, Laura M. De Castro, MD, Tosin Ola, BSN, RN, Lakiea Bailey, PhD
Journal: Blood
Blood (2016) 128 (22): 5921.
https://doi.org/10.1182/blood.V128.22.5921.5921
Published: 2016
Journal Articles

Assessing Perceptions of Hydroxyurea Among Sickle Cell Disease Stakeholders Using Social Media

Aisha L Walker, PhD MPH, Rosta Farzan, PhD, Laura M Gaydos, PhD, Laura DeCastro, MD MHSc, Charles Jonassaint, PhD
Journal: Blood
Blood (2016) 128 (22): 318.
https://doi.org/10.1182/blood.V128.22.318.318
Published: 2016